Introduction

One of the first illness to be identified with distinctive term that was gouty arthritis. In 2640 BC, the Egyptians made their initial discovery. Independence Day’s proclamation singing, the Constitution’s enactment, purpose of the American Revolution has been affected with gout. Comte de Vergennes Along with Thomas Jefferson were essential to acquire the funding to support the revolution, along with Benjamin Franklin, the only person having ratified the three foundational declarations for the United States of America, each had to suffer from severe gout. Franklin had reportedly complained from severe gout that he would have to be carried to the Constitutional Convention in a sedan chair by individuals. Some have suggested that the reason these central figures in American History were so interconnected because they all suffered from gout. ^1,43. Hippocrates later identified in the fifth century, Podagra first developed in the fifth century B.C, calling it ” unwalkable illness” sickness”. Aphorisms that have been recorded by Hippocrates almost 2500 years ago remain preserved. Some of his exceptional clinical findings about gout still remain relevant. ². Hippocrates also kept track of with connection between the illness and an excessive referring to podagra as a way of life “arthritis of the rich” which is in stark contrast to rheumatism, “arthritis of the poor. Galen was the first to describe tophi, six hundred years later precipitated amounts of monosodium urate that can develop following protracted gout. He linked hyperuricemia to depravity an inherited characteristic as a hereditary trait. ³. Roman senator Seneca noted. the occurrence and severity of hyperuricemia has increased worldwide in tandem alongside increasing levels of income and western influence of diet and lifestyle.

Gout has historically been viewed as largely a male disease. Seneca observed that that gout can also affect women and males Gout is predominantly a male disease. During the reign of Nero (AD 54-68) as the first individual to recognise that gout can also affect women. Gout is predominantly a male disease in the present period although it has started affecting women more regularly, particularly after menopause. ⁴.

First to do so was Dominican monk Randolphus of Bocking, domestic chaplain to the Bishop of Chichester allude to podagra as arthritis. Copeman makes reference to a statement made in the London Times in 1900 in his highly regarded study on the progression of gout, typical illness is aptly called yet, gout appears to improve the patient’s social position straight away. In another punch article from 1964 In accordance with the spirit of Gout is becoming less of an elite disease and is now accessible to everyone in more recent times. irrational to prohibit someone getting arthritis since he visited an incorrect establishment. Colchicine is an alkaloid produced from the autumn crocus presumably served as an effective More than 2000 years ago, purgative was used in ancient Greece but Alexander of Tralles , a Byzantine Christian physician , is attributed to establishing it as discerning fixated therapy of arthritis in  sixth century AD. Even though Colchicine was used to treat acute gout, the severe gastrointestinal side effects had been understood before it was authorized for treatment. For approximately 150 years, colchicine was not used to treat gout owing to Thomas Syndeham’s meaningful impact, who objected of all purgative medication as being hazardous and unproductive. William Cullen, a physician from Edinburgh, stated an Attacks of hyperuricemia in individuals, skin is especially in men of a choleric-sanguin type, coated in a thick rete mucosum with a rough surface (Whose father was hurt), is the first one to connect gout to a few outside and perhaps acquired physically characteristics. In 1771, Willaim Cadogan argued, If the exterior of the body and the traits of the countenance are, are commonly familial, could it not be done internally as well William Pitt the Elder, a British statesman debilitating gouty arthritis was a significant factor in the british surrendering the colonies in the United States of America surrendering. During one of Pitt’s gout-related absences from Parliament, the Stamp Act (1765) was approved compelled colonists were required to pay an assessment imposed enacted by the British lawmakers to offset expenditures associated with protecting the colonies from the against the invasion by France. When he recuperated from his arthritis, he used a notorious remark,’’Americans are sons of England, they are not the fools They deserve to extensive involvement as subjects and they can’t be compelled paying taxes without their permission. Sadly, Lord Townsend convinced the legislature to impose a on colonial import for obtaining the needed revenue because of Pitt’s absence a special tax on colonial tea imports in order to obtain the needed revenue during another of Pitt’s absences induced by the gout illness. This triggered the 1773 event of Boston Tea Party, after which history was made. ⁵.

The phrase is derived from the Latin word gutta, which meant “drop” and was used to describe prevalent historical the notion that under certain circumstances, an excess of one of the “four humors” conditions which in homeostasis were supposed to promote health. Thomas Syndenham,  a very-well known well known medical expert from England who was a supporter  of hippocratic therapy later decapacitated from kidney and arthritis ailments illness describes gout as follows : affected patients sleep and is comfortably sleeping before the pain that wakes him up at around two in the morning that  affects the big toe too may also impact the leg’s calf, heel and the ankle. Agony is comparable to broken bone and it is accompanied with tremors, shivering and slight fever. The pain is so brutally painful that it is unable to bear the burden of clothing or trembling of an area made by anyone moving quickly through it.

Gout has a rich history of it being linked to rich foods and excessive drinking. Gout has been termed the “disease of kings” since they are obviously connected with a way of life historically that could only be maintained amongst wealthy people. Arthritis was formerly believed as socially desirable because it was so frequent among the influential and the wealthy. Gout attacks were formerly believed of as a safety precaution against more severe diseases ⁶.  Arthritis stops related maladies which extends the life – span of individuals, in the terms of the historian Horace Walpole said ‘In order to treat arthritis; would I still need high body temperature, palsies or apprehensions.’ ⁷.

Although the nutrition and way of living has changed recently habits which render people more susceptible in the case of arthritis and decrease secretion of uric acid has increased. Imbalance in hyperuricemia occurrence in the Asian subcontinent and the European union demonstrates that increased nutritious purine molecules (Alchohol, steak and other non – vegetarian food) have while developing the illness. Alchohol rare in customary Asian cuisines that basically feature veggies and grains and include few amounts of traditional foods. Food intake by people in affluent nations like the United States of America and Europe richer in various seafood options are in contrast related with rheumatism and osteoarthritis. ^8,9

Role Of Uric Acid In Gout And Hyperuricemia Disease

Although Uric Acid’s Chemical make – up wasn’t known yet, crystals from a tophus with gout had first been observed by Leeuwenhoek, who was a trailblazer in the field of microbiology. In 1679 he wrote, “To my astonishment, I found that the solid substance that appeared as chalk was actually comprising of long, transparent particle, the majority of which were pointed at both ends and stretched about four times longer as that of the globules’ “axes”. I can’t imagine a better way to describe this than to state that we saw with my own eyes pieces from a horsetail that were each one sixth inch long” ¹⁰. William Stukeley, a physician and famous antiquarian experienced hyperuricemia symptoms described the crystals prevalent in his tophaceous joint 55 years later. ¹¹. The Swedish chemist Scheele first identified uric acid’s chemical makeup as a component of the kidney stones in the year 1776. ¹². In 1797, a scientist from England, Woolaston demonstrated a tophaceous specimen that showed urate just by blowing into it. ¹³. In a semi – quantitative method for determining uric acid in blood and other fecal matter which was demonstrated by scientist Sir Garrod fifty years later by the thread test, which is the first ever diagnostic screening analysis performed. ¹⁴. As according to Garrod’s work, which was published in the year 1859, “the precipitated soda urate could be viewed as the root source rather than the outcome with regards to inflammatory arthritis. ¹⁵. 

This hypothesis later ended up receiving experimental support from Freudweiler’s discovery that subcutaneous injection comprising nanocrystals of urate could induce tophi to emerge and his work establishing that intra-articular injection of urate crystals could trigger osteoarthritis. Before McCarty and Hollander’s pivotal publication which revealed monosodium urate crystals were found in the fluid from the synovial joints of people suffering with hyperuricemia, these experiments went largely unnoticed for more than five decades. Compressed fluorescence microscopy was applied to detect synovial fluid aggregates of calcium pyrophosphate dehydrate fluids with individuals suffering from the painful form of arthritis that causes calcium pyrophosphate crystal deposits in the joint tissues and hyperuricemia following their classic report on the topic documented the use for analysis of joint fluid to check for nano – particles. Areteaus,  a prominent Cappadocian physician , initially diagnosed a gouty “diathesis” in the second century AD , implying that gout could be inherited. ^16-20.                                        

Treatments for Gout and Hyperuricemia Employed in Ancient Times

Sir Archibald Garrod did not suggest arthritis as a disorder which may have been brought on by inherited metabolic flaws until 1931. Moreover, initial nucleoside enzymatic deficit related to sort of hereditary arthritis wasn’t identified till the year 1957. The renowned scientist Seegmiller with his associates observed an influence in terms of excess urate production and poor excretion in the pathophysiology of arthritis. Professor Baron Van Stoerk in Vienna rediscovered Colchicine; which wasn’t used in the gout treatment for the past 150 years. Medications that are non – anabolic which suppress inflammation are currently used in the predominant therapy for severe arthritis while intra – articular or systematically administered corticosteroids and targeted cyclo-2 antagonists are less frequently utilized to treat individuals’ sudden seizures who’ve had prohibition against non – anabolic medications. ^21-25.

Despite the fact that food represents a key aspect, pathophysiology of arthritis along with changes in diet as the method as to gain control over arthritis and elevated uric acid level has been generally ignored. The notion that hyperuricemia could be mitigated by ingesting fewer foods rich in protein was first brought forward by AB Garrod. This was validated by Haig’s clinical experiments on himself throughout 1894 to 1897 and beyond recent clinically psychological study with individuals who had been provided gluten protein – free diets and liquids. The use of uricosuric agents, which accelerate renal urate clearance, originates from the late 19^th century. By administering a gout patient; large doses of salicylates proved effecting at causing uricosuria to cure tophus. Additionally to urate excretion, salicylates have a bimodal impact at lower concentrations which blocks urate secretion, while in higher concentrations (4 to 6 grams per day), it possesses uricosuric characteristics. Salicylate drugs, however weren’t employed as uricosuric agents and were made obsolete by probenecid, sulfinpyrazone and benzbromarone for the reason that it is poisonous and impractical in higher doses. More recently it was discovered that the lipid-lowering fibrate fenofibrate and drugs like losartan which lowers the blood pressure is classified as an inhibitor of angiotensin, had very modest uricosuric effects, although neither of those drugs are authorized to treat gout or hyperuricemia. ^26-36.

The bulk of the species of mammals which generate uricase which changes urate into more permeable nature which rapidly excretes the substance allantoin, maintaining low uric acid range that do not exhibit arthritis. In the later half of the 1960’s, initial assessment was published by scientists on the administration of uricase to two people, one of whom has an extensive record of conventional arthritis associated with gout and another person not having problems associated with gout before. The scientists found that refined uricase which has strong uricolytic action when given intravenously by evaluating serum uric acid levels and urinary allantoin levels. Recombined fungicidal synthetic porcine uricase that has proven beneficial for the treatment of cancer patients’ acute uric acid nephropathy caused about by cell lysis. Fungal uricase helps treat chronic gout however its prolonged use has been constrained with its minimal half-life alongside possible intolerance. Synthetic uricase used in protracted rehabilitation of hyperuricemia is under phase III trials. ^37,38.

First inhibitor of xanthine oxidase; Allopurinol, may well have signified an essential historic breakthrough for diagnosing gouty arthritis. Due to the synthesis of allopurinol and azathioprine along with five essential medicines, the duo of Hitchings and Gertude were conferred the noble prize in the year 1988.  Ever since, allopurinol has eclipsed most other uric acid lowering drugs in clinical use. The development of tophaceous deposits has already been shown to be averted by drugs like allopurinol operate with blocking the numerous xanthine derivatives. They are efficient at decreasing urate levels in the blood and urine. Allopurinol’s active metabolite, oxipurinol has been accessible with humanitarian purpose in several nations with another drug febuxostat, which already finished phase two and phase three investigative studies that illustrated how effectively it lowered concentration of uric acid in individuals suffering from persistent arthritis. ^39-43.

Prescription medications used for of arthritis

Topiroxostat

Prominent Japanese scientists Sanwa Kenkyusho and Fuji Yakuhin teamed up to create and commercialize Topiroxostat, which is heterocyclic, selective inhibitor of xanthine oxidase initially in the year 2013 saw approval for its application in Japan. It is in the form of oral tablets in strength beginning with 20, 40 and 60 mg with the common advice to begin at twenty mg two times in a span of 24 hours. The maximum approved dose is 80 mg twice daily and therapeutic efficacy was observed at 120 mg per day. The enzyme activity has been demonstrated to be inhibited by Topiroxostat through a two- pyridine derivative that has been hydrogenated which combines with the solvent channel’s amino acid residues and produce the chemical attachment with molybdenum using oxygen. ^44-47.

Benzbromarone

Following a report of idiosyncratic hepatotoxicity, United States of America did not authorise benzbromarone hence it was subsequently discontinued in various nations around the early 2000’s. Studies demonstrate that Benbromarone performs effectively as a single unit ULT, with a 200 mg/day dose attaining target serum urate levels in 92% (22-24 people) of gout patients. It should be noted that both benzbromarone and allopurinol performed equally whenever the levels have been raised in a subsequent study whenever patients were unable to maintain adequate control at the start of the treatment. ^48-49.

Lesinurad

The clinical programme was continuing to be developed by Ardea after the company was purchased by AstraZeneca in 2012. Lesinurad is much more efficient as compared to xanthine oxidase inhibitors alone at reducing urate in certain individuals as per the phase II clinical trials. In the following three pivotal phase trials, persons with arthritis receiving allopurinol also received Lesinurad. Adults with rheumatism who take allopurinol alone or combined with febuxostat subsequently reported an unsatisfactory response. Lesinurad and febuxostat have been used in the 12-month CRYSTAL experimental trial of patients with tophaceous gout to evaluate the safety and efficacy of the therapy. 400 mg of Lesinurad alongside febuxostat, significantly more patients (76.1%; P 0.0001) than it was with febuxostat alone (46.8%) achieved desired target serum uric acid level of 5.0 mg/dl as its main objective did not react significantly to the 200 mg dose of Lesinurad ; nonetheless , every other parameter was evaluated , a large number of individuals in this category met the goal. The number of patients with complete tophus remission didn’t differ significantly between the groups. However, compared to febuxostat alone (28.3%), the Lesinurad (600 mg), In general overall tophi surface was significantly reduced in this febuxostat group. In Overall TEAE rates, there were similarities between the groups yet the kidney’s TEAE rates appeared marginally greater among Lesinurad 200 mg combined group with febuxostat (8.5%) along with Lesinurad 400 mg plus febuxostat category (10.1%), compared to febuxostat (5.5%). That’s because of greater concentration of  is higher than normal blood creatinine values after taking Lesinurad. Lesinurad 400 milligrams combined with febuxostat was given to a couple of individuals. Failure of the kidneys with severe pains in two individuals with one individual using febuxostat for extreme kidney damage witnessed significant TEAEs associated to kidneys, whereas no one taking Lesinurad 200 milligrams with febuxostat group. At the end of 2015, the FDA granted approval to the use of 200 milligrams Lesinurad in hyperuricemic individuals attributable to arthritis who hadn’t effectively reached desired blood urinary acid levels after the administration of only the xanthine oxidase antagonist. The administration is restricted amongst the individuals who suffer from severe kidney damage, patients who require an urgent kidney transplantation, individuals on dialysis and individuals with tumour lysis. Extra information regarding data, various in-depth investigations in regard to the drug has been released giving comprehensive explanation about the composition. ^50-53.

Urate Degradation by Uricases

The dearth of a functioning uricase enzyme differentiates humans and as well as several primate species from other mammals. Uric acid is transformed through uricase into the more conveniently expelled allantoin, which is more water soluble. In a bid to attain a rapid and substantial decrease in serum urate amount, there are currently established treatments based on the delivery by IV administering of a functioning transgenic uricase enzyme. For handling persistent arthritis in individuals with comorbidities and deformities, 2010 saw the approval of Peglitocase. It is inserted into a vein in doses 8 mg every two weeks for the duration of 180 days. Experimental studies revealed 47% respondants as compared to inactive substance. Pegloticase; nevertheless is connected to a major prevalence regarding sudden flare-ups, because of probable fast secretion of uric acid decrease induced due to the intake. It has been successfully applied at healthcare settings although in addition to vulnerable individuals who have allergies, number of individuals becoming immune to the remedy during the initial days. During medical investigations, adverse effects like dyspnea, chest discomfort, and flushing occurred in 26-41% patients. Patients who had elevated levels of Pegloticase antibodies reported these reactions regularly. Treating patients with antihistamines or corticosteroids carries potential for problems might problems in people having past medical history about cardiac diseases as the consequence of decreasing the infusion reactions. ^54-55.

Rasburicase was recently permitted to treat arthritis linked to the disease which ruptures cells because Pegloticase’s relatively brief half – life and mode of action (eight hours compared to 12 days) align comfortably in its applications. Thus it is used in the initial control of serum urinary concentrations adults alongside individuals affected by cancer, blood cancer and tumors being treated with curative medication that may cause cell death eventually increase uric acid concentration in blood. Furthermore, extreme incidences regarding methemoglobinemia, hemolysis, immune stimulating medications events, along with hypersensitivity in individuals restrict the use of Rasburicase in a wider context. ⁵⁶.

Selected Drugs with Negligible Recent Clinical Progress

There are several recent compounds for which no existing clinical activity has been documented besides all of the preceding substances seem to be still moving forward in research studies. Among those are different types are Xanthine oxidase antagonists for the treatment of elevated level of uric acid in individuals with arthritis, such as LG Life Sciences’ LC350189. The proposed repurposing of trainlast, a stimulative medication medication that is extensively utilized a lot since years in the treatment of bronchitis in Japan which also had an additional uricosuric influence, seems to be another alternative uricosuric compound that has progressed into clinical trials. Later with to Urate Transporter 1, Organic Anion Transporter 4, and Organic Transporter 10, its impact assists in moderate suppression of Glucose Transporter 9. Furthermore, NPT1, OAT1, and OAT3 appear to belong to the secretory urate transporters which tranilast seems to inhibit numerous uric acid luminal carriers such as Sodium Dependant Phosphate Transport Protein 1, Organic Anion Transporter 1 and Organic Anion Transporter 3 that could sometimes significantly be contributing to the result. In partnership with Pfizer, Kissei Pharmaceuticals evaluated PF-06743649, unique double Xanthine Oxidase and Urate Transporter 1 Suppressor, till the second stage of medical experiments employed in the treatment of arthritis. Ultimately, research trials got terminated due to unanticipated renal safety issues. As a substitute to XO inhibitors, uricosuric, and uricolytic drugs, ulodesine (BCX4208) exhibited a different method of action. This is an effective inhibitor of purine nucleoside phosphorylase (PNP) which acts prior to xanthine oxidase inhibitors. ^57-62.

Is Hyperuricemia a Genetic Disorder?                                                                

 It has been demonstrated several times both hyperuricemia and hyperuricosuria cluster families and thus transmitted in a familial fashion. In South American families, studies, heritability varied from 39 to 45%. Likewise, both adults and children exhibited genetic mutations which impacted baseline renal urate excretion level. More than 140,000 individuals of European descent took part in a GWAS that discovered uric acid receptors which are codified by twenty-eight chromosomal genes which impacts the plasma uric acid levels. ^63-64.

 Inspite of having the advantage of shared biological origins in twin studies specific arthritis symptoms variance revealed that it is considerably affected with the common external variable effects by twins instead of hereditary influences as per models that evaluated the comparative influences of genetic and environmental factors on phenotypic polymorphism. Individual variances in arthritis meanwhile determined with hereditary factors. GWASs check variety found in variations within numerous people’s genes to see if a variant has been connected to a specific trait. Although candidate gene studies have demonstrated the genetic code associated with Pyrine Domain Containing Protein 3 stimulation along with functioning of the cytosolic multiprotein oligomers while suffering from gout, there are several genome-wide associated studies with limited success ^65-69.

Urate Generation Inside the Body

Accelerated cellular turnover disorders like malignancies, haematological disorders and inflammatory conditions lead to a higher endogenous uric acid generation. Additionally, chemotherapy and tissue damage may result in an increase in purine biosynthesis. Furthermore, obesity and greater body weight increase the production of uric acid, that raises the likelihood of hyperuricemia. Serum urate levels were found to be drastically improved in reaction to leptin. Hence, lowering serum urate levels could be achieved by weight loss and exercise. ^70-73.

Decreased Excretion of Uric Acid

There are four phases which result in the renal excretion of uric acid. The reabsorbing from salts of uric acid flowing through adjacent vessels accompanies the passage of UA through the Bowman’s capsule in the first phase (glomerular filtration). Another reabsorption phase within adjacent vessels after third stage, that includes emitting a portion of resorbed uric acid. Bowman’s capsule screens urate; nearly 10% of that is excreted, with the rest getting reabsorbed by the body. Some autosomal dominant is related to reduced renal excretion of urate. Large ascending portion of the henle loop contains the gene uromodulin. It regulates how porous the water is. Fractional excretion of UA becomes lessened as a result of uromodulin gene mutations, which elevates SUA. Through an active transport process, Urate Transporter 1 carries uric acid from filtrated liquid which enters the distal vessels by means of tubules. Probenecid, benzbromarone, and sulfinpyrazone instances known of uricosuric drugs which inhibit URAT1 activity and, as a result, UA reabsorption inside the vessels. In contrast to medications that enhance the uric acid uptake by influencing Urate Transporter 1 urate reabsorption by acting on URAT1, that transfers uric acid through helical cell’s loop from the source which boost inhibiting the elimination in urine through tube resorption and the filtration of uric acid elevating uric acid level in the blood. According to the dose, materials which modulate Urate transporter 1 action would either enhance or prevent it. For example, aspirin seems to show the action that relates to excretion of uric acid from the urine in lower doses and exhibiting a uricosuric effect with high doses. Since aspirin at large concentrations inhibits URAT1, it exerts an uricosuric effect. Another title of this process is cis-inhibition of URAT1. Aspirin’s trans-stimulation of URAT1 culminates in the anti-uricosuric effect. ^74-77.

Regulating Uric Acid Producing Genes

Urate transporter 1 located in an area alongside apical membrane, the ureteric vessels was accounted for by the SLC22A12 gene. Another gene which regulates UA excretion is SLC2A9. It designates a transporter protein for the renal tubule membrane. Both genes’ polymorphism results in a decrease inside the fraction of UA expelled that increases overall levels of SUA. Both in the GIT as well as corpuscles found in proximal region of kidneys, ABCG2 serves being an uric acid genre transporter. kidneys’ SLC17A1, SLC17A3, that functions as membrane transporters, are important controllers regarding serum uric acid concentration. Organic anion transporter 4, controlling enzyme of glucose, CARMIL 1 gene with protein coding gene that is associated with hyperuricemia include further gene mutations responsible for determining SUA levels. ^78-79.

Gouty Arthritis’s Acute Pathogenesis

Initial cause of gout is the particles containing uric acid crystals accumulating inside the joint’s region. Getting absorbed due to the gram – positive cells in the synovium, these crystals commence the inflammatory reaction by unleashing proteins within lysosomes generating incendiary cytokines. There is an additional system in which uric acid crystal effectively crosslink which consists of erythropoietin alongside phospholipids to modify stability regarding phagocytic cell’s cell walls. G- protein, ephrin receptor tyrosine kinase, mediator enzyme C, mediator enzyme D, nitrogen stimulated enzymes, Keratin protein kinase as well as additional enzymes are mostly activated with this mechanism. Because of this interaction, phagocytes release additional IL-8, that stimulates neutrophils. Neutrophils become triggered following monocytes and mass cells in the pathogenesis of gouty arthritis. Macrophages devour UA crystals all through the internal-critical period and before the first gout attack. These crystals could be controlled by the well-differentiated macrophages without generating an inflammatory response. While recovering the original urate crystals, lesser advanced macrophages create massive quantities which includes Tumor Necrosis Factor, Interleukin factors 1, 6 and 8 in addition to stimulating endothelial platelets. Mast cells have the most critical step for initiating an episode of arthritis with depositing neuromodulator and Interleukin – 1. Vasodilation and vascular permeability also increase as a result. It’s fascinating to note that absorbing microscopic particles as well as the debris of inflammation, it may even terminate the inflammatory phase. 90% of the neutrophile activation and acute inflammation in the synovium is caused by overproduction of metabolic elements including eicosanoids, AGEPC (Acetyl-glyceryl–ether-phosphorylcholine) along with cytokines and especially Interleukin-8. As a consequence, stopping a gout attack can be avoided through suppressing IL-8. Neutrophil chemotaxis is triggered by chemicals made up of mastocytes and platelets in addition to vasodilation. Furthermore, the stimulation of cells in microvascular tissues affects any reactionary process along with neutrophil movement. Local neutrophil concentrations increase as a consequence. Colchicine is thought to function through modulating relationships between selections on Intemperate cytokines acting upon monocytes and cells of the endothelial system including preventing vascular cell-induced stimulation of White blood cells to prevent the acute attack. Gout episodes are generally self- limited. Within a few hours to days, it subsides. These is effedcted by macrophages eliminating the crystals and eating away, that suppresses stimulation of chemical messengers with cells. Likewise, phagocytes eliminate leftovers of lymphocytes which have perished to terminate the cycle of inflammation. In addition to the monocytes produce Transforming growth factor which inhibits Interleukin-1, one of the essential component that causes inflammation. Whenever it comes to lowering irritation, anti-inflammatory cytokines become critical. Proteolysis of pro-inflammatory cytokines and a reduction in the expression of TNF and interleukin receptors on the surface of leukocytes constitute two new mechanisms which assist to terminate the acute attack. The potential of macrophages to extravasate in the body part and clear the inflamed area to be cleared relies on vascular elongation and greater permeability. ^80-85.

Managing Chronic Gout and Avoiding Flare-Ups

Serum urate level ought to reduce the numbers those that ought to be less comparable Midstream Saturation Point in order to reach MSU crystal dissolution. The SYA target recommended to the ACR and EULAR, ought to be below 6mg/dl among individuals having gout and beneath 5mg/dl in people suffering from extreme arthritis for enabling faster crystal load disintegration. Constant surveillance with regards to SUA levels is necessary for identifying hyperuricemia. Regarding epidemiologic research that demonstrated how much the lifestyle factors influenced gout, EULAR and ACR recommended obese patients to shed weight, avoid consuming alcohol, added sugars, beer, and seafood, restrict intake of meat, and ingest extra skimmed milk products as well as increased physical activity. To avoid flares and recurrence of crystal formation, uricemia should be controlled persistently under 6mg/dl. Over time, uricemia should be assessed every six months. Due to crystal activation, the onset of urate lowering drugs increases the likelihood of gout flare-ups. Particularly, as the deposits start to degrade, there is an increase in fragility with particulates made spill over through the joint spaces area that triggers the swelling. Individual in question should be informed of the danger should be decreased by gradual adjustments with regards to the titrimetry the urate lowering drugs as well as drugs in limited doses. Over-time preference for urate lowering drugs has risen as a result of the improved understanding of the adverse implications and consequences related to hyperuricemia affecting the heart and blood vessels with the reality which suggests individual affected by arthritis for a considerable time is linked to multiple chronic conditions in addition to substantial midstream specimen of urine smears that impede crystalline disintegration. Regular EULAR recommendations state that urate lowering drugs are highly suggested to patients is evident which is common practice seen along with addition to those patients who have comorbidities with their cardiovascular health or kidneys, have high uricemia (8mg/dL), are young (40 years old), or are likely to encounter frequent attacks. The EULAR suggests speaking to the patient about the potential of the urate lowering drugs as soon as the first flare arises in individuals with a definitive diagnosis of gout. Since gout flares occur frequently and NSAIDs, colchicine, and steroids are contraindicated, the EULAR recommends patients to consider administering IL-1 blockers (oral or injectables). To improve human health, it is crucial to test and treat patients having gout for vascular and hepatic conditions along with metabolism disorders which suggests to give up smoking. Mitigare and corticosteroids are gout flare medications that are administered when complications arise. This mode of treatment is successful if it is given immediately following the flare- up begins.  Based on this, Various international medical committees have recommended that how individuals themselves have to be in administering medications themselves. Inadequate use of medications which reduce uric acid in the body is often responsible with regards to the failure, highlighting the significance of patient and physician education.^86-90

Changes in diet appear to be less effective at managing hyperuricemia than ULD. However, a combination of both is extremely beneficial for treating severe arthritis. Additionally for enabling a minimum serum uric acid depletion: daily habits, exercise along with weight reduction are essential factors in controlling complications related to heart along with diseases related to arthritis. It has already been proven that changing one’s diet to treat metabolic syndrome or hypertension reduces uricemia. Gout treatment which directly addresses SUA causes in the long-term eradication of disease symptoms. ^91-95.

Alternative for Hyperuricemic Drugs

Drugs that increase uricemia should be prevented whenever feasible. Antihypertensive medicines likely to be the main exception to this norm. Administration of high ceiling diuretics along with drugs like metalozone increases incidence of arthritis on average 0.65mg/dl and 0.96mg/dl respectively. Also associated to as higher arthritis susceptibility includes drugs like Acebutolol and Atenolol along with angiotensin receptor blockers and drugs falling under angiotensin converting enzyme drugs. Losartan and calcium channel inhibitors must be emphasized. When possible, spironolactone, was possesses minimal effect upon the urate level is prescribed in cardiac failure. Drugs such as Aspirin moderately increase arthritis with clopidogrel used as a substitute is also a possibility. ^96-98.

Use of Rate Oxidases in Hyperuricemia Treatment:

Elitek and recombinant urate oxidase have been granted approval to cure cancer lysis syndrome. Its unauthorized use in tophaceous gout has been documented. Pegloticase is a peglyated Uricase which has been approved to treat severe arthritis which is unresponsive to ULD’s in the USA and Europe. It is also commercialized internationally. The drug, that is extremely effective, is given through intravenous injections (dose is 8 milligrams in 14 days). About half of the patients show increased antibody formation, that limits uricemia response and enhances the chances regarding extreme complications. Therefore, it is suggested that for monitoring arthritis 24 hours before each scheduled dose and not administer the drugs in case the intensity of arthritis isn’t decreasing. To keep this warning signal functional, no alternative ULD should be administered simultaneously. Losartan and calcium channel inhibitors are recommended for the treatment of hypertension, statins or fenofibrate are preferable for the treatment of dyslipidemia and insulin-lowering drugs are used for the treatment of diabetes mellitus. Furthermore, Sodium-glucose cotransporter-2 drugs show remarkable potential for decreasing urate levels. ^99-102.

Conclusion

The drastically changing food habits and modern lifestyle has led to the increased incidence of gout and hyperuricemia. Many physicians have invented various forms of treatments throughout history and the methods of treatment have evolved over the years as well with different breakthroughs giving significant insights into various ways of managing gout and hyperuricemia. Due to the intake of purine-rich diets and changing lifestyle habits and eating choices, incidence of gout and hyperuricemia are on the rise. With constantly evolving medical technology, methods of treatment for hyperuricemia and gout have also gone under drastic transformation and the effectiveness of treatments have increased manifold due to the use of Xanthine oxidase inhibitors like Allopurinol and Topiroxostat. Management of hyperuricemia and gout by people and increased awareness about the side-effects will also go a long way in making the people realize the consequences of this disease. In the past, gout used to affect large number of males. In comparison, the number of females that suffered from gout and hyperuricemia were less in number but nowadays the incidence of the disease has increased in females as well which is a cause of concern. The tremendous advancement with regards to the medications available for treating arthritis have made the mode of treatment easy and affordable which provides relief to the patients. The anti-inflammatory therapy has shown impressive results in combating the disease with nonsteroidal anti-inflammatory drugs and glucocorticoids playing an important role. Continued research is carried out to find new drugs and formulation and improve the quality of existing drugs that are currently in use to treat gout and hyperuricemia which has the capacity to make a positive impact in the dosage regimen of patients. The awareness of gout and hyperuricemia should be raised more amongst the people by health-care professionals so that the people will know the harmful consequences of this disease and will take appropriate steps to make sure that they control their uric acid intake and maintain the uric acid levels in the body below the threshold so that they could avoid hyperuricemia and gout. New research in the treatment of hyperuricemia and gout should be encouraged so that more affordable and effective treatment can be administered to the patients in the future. It is imperative that the treatment of hyperuricemia or gout is initiated as quickly as possible because if this disease is not treated quickly, it has the potential to turn into a chronic disease hence it becomes absolutely vital to follow all the necessary treatment protocols prescribed by the physician and religiously adhering to the dosage regimen so as to avoid further complications. New research is constantly being carried out to discover other modes of treatment to cure hyperuricemia and gout.

Acknowledgement

The authors are thankful to the management of college for providing necessary facilities and Principle Dr. L. B. Borse for their constant support, expert advice and encouragement to write this review article.

Conflict of Interest

There is no coflict of Interest.

Funding Sources

There is no funding sources

References

1. Schwartz, S. A. (2006). Disease of distinction. Explore, 2(6), 515-519.
2. Adams, F. (Ed.). (1886). The genuine works of Hippocrates(Vol. 1). W. Wood.
3. Kühn, C. G. (1965). Galen (eds) Claudii Galeni opera omnia. 20 Bde Leipzig: Cnobloch 1821–1833. Neudruck: Hildesheim: Olms.
4. Garrison, F. H. (1928). History of medicine, 1929. Albert Guerard, The Life and Death of an ideal.
5. Copeman, W. S. C. (1964). A short history of the gout and the rheumatic diseases. Univ of California Press.
6. Nuki, G., & Simkin, P. A. (2006). A concise history of gout and hyperuricemia and their treatment. Arthritis research & therapy, 8(1), 1-5.
7. Lewis, W. S. (Ed.). (1937). The Yale edition of Horace Walpole’s correspondence. Yale University Press.
8. Zöllner, N. (1973). Influence of various purines on uric acid metabolism. Clinical Nutrition, 19, 34-43.
9. Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W., & Curhan, G. (2004). Purine-rich foods, dairy and protein intake, and the risk of gout in men. New England Journal of Medicine, 350(11), 1093-1103.
10. McCarty, D. J. (1970). A historical note: Leeuwenhoek’s description of crystals from a gouty tophus. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 13(4), 414-418.
11. Nuki, G., & Simkin, P. A. (2006). A concise history of gout and hyperuricemia and their treatment. Arthritis research & therapy, 8(1), 1-5.
12. Scheele, K. W. (1776). Examen chemicum calculi urinarii. Opuscula, 2(73), 1776.
13. Nuki, G., & Simkin, P. A. (2006). A concise history of gout and hyperuricemia and their treatment. Arthritis research & therapy, 8(1), 1-5.
14. Garrod, A. B. (1848). Observations on certain pathological conditions of the blood and urine, in gout, rheumatism, and Bright’s disease. Medico-chirurgical transactions, 31, 83.
15. Garrod, A. B. (1859). Treatise on nature and treatment of gout and rheumatic gout. London: Walton and Maberly.
16. Freudweiler, M. (1898). Experimentelle Untersuchungen über das Wesen der Gichtknoten... Verlag nicht ermittelbar.
17. His, W. (1900). Schicksal und Wirkungen des sauren harnsauren Natrons in Bauch-und Gelenkhöhle des Kaninchens. Vogel.
18. MCCARTY, D. J., & HOLLANDER, J. L. (1961). Identification of urate crystals in gouty synovial fluid. Annals of internal medicine, 54(3), 452-460.
19. MCCARTY JR, D. J., Kohn, N. N., & Faires, J. S. (1962). The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the” pseudogout syndrome” I. Clinical aspects. Annals of Internal Medicine, 56(5_Part_1), 711-737.
20. Adams, F. (Ed.). (1856). The extant works of aretaeus: the cappadocian(Vol. 27). Sydenham Society.
21. Garrod, S. A. E. (1931). The inborn factors in disease: an essay. Clarendon Press.
22. Seegmiller, J. E., Rosenbloom, F. M., & Kelley, W. N. (1967). Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science, 155(3770), 1682-1684.
23. Seegmiller, J. E., Grayzel, A. I., Laster, L., & Liddle, L. (1961). Uric acid production in gout. The Journal of clinical investigation, 40(7), 1304-1314.
24. Stoerk, A. (1764). An Essay on the Use and Effects of the Root of the Colchicum autumnale, or Meadow Saffron, Translated from the Latin. London: T Becket and PA de Honet.
25. Neogi, T. (2011). Clinical practice. gout. N Engl J Med, 364, 443-452.
26. Garrod, A. B. (1876). A Treatise on gout and rheumatic gout (rheumatoid arthritis). Longmans, Green.
27. Nuki, G., & Simkin, P. A. (2006). A concise history of gout and hyperuricemia and their treatment. Arthritis research & therapy, 8(1), 1-5.
28. Griebsch, A., & Kaiser, W. (1976). Einfluss exogener purine auf den harnsaurestoffwechsel. Handbuch der Inneren Medizin.
29. Kippen, I., Whitehouse, M. W., & Klinenberg, J. R. (1974). Pharmacology of uricosuric drugs. Annals of the rheumatic diseases, 33(4), 391.
30. Sée, G. (1877). Etudes sur Iraida salicylique et les salicylates; traitement due rhumatisme aigu et chronique de la goutte, et de diverses affections du syste’nerveux sensitif par les salicylates. Bulletin de L’Academie Nationale de Medicine, 26, 689-706.
31. Gutman, A. B. (1959). Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. The Journal of clinical investigation, 38(8), 1298-1315.
32. Talbott, J. H., Bishop, C., Norcross, B. M., & Lockie, L. M. (1951). The clinical and metabolic effects of benemid in patients with gout. Trans Assoc Am Physicians, 64, 372-7.
33. Burns, J. J., Yü, T. F., Ritterband, A., Perel, J. M., Gutman, A. B., & Brodie, B. B. (1957). A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. Journal of Pharmacology and Experimental Therapeutics, 119(3), 418-426.
34. Delbarre, F., Auscher, C., & Amor, B. (1965). Action uricosurique de certains derives du benzofuranne. Soc Med Hop Paris, 116, 1193-1196.
35. Kamper, A. L., & Nielsen, A. H. (2001). Uricosuric effect of losartan in patients with renal transplants. Transplantation, 72(4), 671-674.
36. Feher, M. D., Hepburn, A. L., Hogarth, M. B., Ball, S. G., & Kaye, S. A. (2003). Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology, 42(2), 321-325.
37. London, M., & Hudson, P. B. (1957). Uricolytic activity of purified uricase in two human beings. Science, 125(3254), 937-938.
38. Bosly, A., Sonet, A., Pinkerton, C. R., McCowage, G., Bron, D., Sanz, M. A., & Van den Berg, H. (2003). Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer: Interdisciplinary International Journal of the American Cancer Society, 98(5), 1048-1054.
39. Rundres, R. W. (1963). Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout. Trans Ass Amer Phycns, 76, 126-140.
40. Walter-Sack, I., De Vries, J. X., Kutschker, C., Ittensohn, A., & Voss, A. (1995). Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. European journal of clinical pharmacology, 49(3), 215-220.
41. Becker, M. A., Schumacher Jr, H. R., Wortmann, R. L., MacDonald, P. A., Palo, W. A., Eustace, D., … & Joseph‐Ridge, N. (2005). Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout. Arthritis & Rheumatism, 52(3), 916-923.
42. Becker, M. A., Schumacher Jr, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., … & Joseph-Ridge, N. (2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine, 353(23), 2450-2461.
43. Nuki, G., & Simkin, P. A. (2006). A concise history of gout and hyperuricemia and their treatment. Arthritis research & therapy, 8(1), 1-5.
44. Gandhi, P. K., Gentry, W. M., Ma, Q., & Bottorff, M. B. (2015). Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a US payer perspective. Journal of Managed Care & Specialty Pharmacy, 21(2), 165-175.
45. Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: aphase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther. (2016) 41:290–7. 10.1111/jcpt.12391 
46. Horino T, Hatakeyama Y, Ichii O, Matsumoto T, Shimamura Y, Inoue K, et al.. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease. Clin Exp Nephrol. (2017) 22:337–45. 10.1007/s10157-017-1452-3
47. Sato, T., Ashizawa, N., Matsumoto, K., Iwanaga, T., Nakamura, H., Inoue, T., & Nagata, O. (2009). Discovery of 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1, 2, 4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia. Bioorganic & medicinal chemistry letters, 19(21), 6225-6229.
48. Pui, K., Gow, P. J., & Dalbeth, N. (2013). Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. The Journal of rheumatology, 40(6), 872-876.
49. Reinders, M. K., Van Roon, E. N., Jansen, T. T. A., Delsing, J., Griep, E. N., Hoekstra, M., … & Brouwers, J. R. B. J. (2009). Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Annals of the rheumatic diseases, 68(1), 51-56.
50. Saag, K. G., Fitz‐Patrick, D., Kopicko, J., Fung, M., Bhakta, N., Adler, S., … & Becker, M. A. (2017). Lesinurad combined with allopurinol: a randomized, double‐blind, placebo‐controlled study in gout patients with an inadequate response to standard‐of‐care allopurinol (a US‐based study). Arthritis & Rheumatology, 69(1), 203-212.
51. Van Ede, A. E., Laan, R. F. J. M., Blom, H. J., Boers, G. H. J., Haagsma, C. J., Thomas, C. M. G., … & Van De Putte, L. B. A. (2002). Homocysteine and folate status in methotrexate‐treated patients with rheumatoid arthritis. Rheumatology, 41(6), 658-665.
52. Hoy, S. M. (2019). Onasemnogene abeparvovec: first global approval. Drugs, 79(11), 1255-1262.
53. Deeks, E. D. (2017). Lesinurad: a review in hyperuricaemia of gout. Drugs & aging, 34(5), 401-410.
54. Robinson, P. C., & Dalbeth, N. (2017). Lesinurad for the treatment of hyperuricaemia in people with gout. Expert opinion on pharmacotherapy, 18(17), 1875-1881.
55. Sherman, M. R., Saifer, M. G., & Perez-Ruiz, F. (2008). PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Advanced drug delivery reviews, 60(1), 59-68.
56. Sundy, J. S., Baraf, H. S., Yood, R. A., Edwards, N. L., Gutierrez-Urena, S. R., Treadwell, E. L., … & Becker, M. A. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Jama, 306(7), 711-720.
57. Yoon, S., Shin, D., Lee, H., Jang, I. J., & Yu, K. S. (2015). Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Design, Development and Therapy, 9, 5033.
58. Mandal, A. K., Mercado, A., Foster, A., Zandi‐Nejad, K., & Mount, D. B. (2017). Uricosuric targets of tranilast. Pharmacology Research & Perspectives, 5(2), e00291.
59. Dua, P., Gurrell, R., Kirby, S., Sudworth, M., & Loudon, P. T. (2016). Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. Clinical rheumatology, 35(8), 2045-2051.
60. Bantia, S., Parker, C., Upshaw, R., Cunningham, A., Kotian, P., Kilpatrick, J. M., … & Babu, Y. S. (2010). Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B-and T-lymphocytes—a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. International immunopharmacology, 10(7), 784-790.
61. Grunebaum, E., Cohen, A., & Roifman, C. M. (2013). Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Current opinion in allergy and clinical immunology, 13(6), 630-638.
62. Benn, C. L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R. I., & Vangjeli, C. (2018). Physiology of hyperuricemia and urate-lowering treatments. Frontiers in medicine, 5, 160.
63. Ko, Y. L. (2022). Genetics of hyperuricemia and gout: Insights from recent genome-wide association studies and Mendelian randomization studies. Tzu-Chi Medical Journal, 34(3), 261.
64. Chittoor, G., Haack, K., Mehta, N. R., Laston, S., Cole, S. A., Comuzzie, A. G., … & Voruganti, V. S. (2017). Genetic variation underlying renal uric acid excretion in Hispanic children: the Viva La Familia Study. BMC medical genetics, 18(1), 1-8.
65. Krishnan, E., Lessov-Schlaggar, C. N., Krasnow, R. E., & Swan, G. E. (2012). Nature versus nurture in gout: a twin study. The American journal of medicine, 125(5), 499-504.
66. Manolio, T. A. (2010). Genomewide association studies and assessment of the risk of disease. New England journal of medicine, 363(2), 166-176.
67. Qing, Y. F., Zhou, J. G., Zhang, Q. B., Wang, D. S., Li, M., Yang, Q. B., … & Zeng, M. (2013). Association of TLR4 Gene rs2149356 polymorphism with primary gouty arthritis in a case-control study. PloS one, 8(5), e64845.
68. McKinney, C., Stamp, L. K., Dalbeth, N., Topless, R. K., Day, R. O., Kannangara, D. R., … & Merriman, T. R. (2015). Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis research & therapy, 17(1), 1-8.
69. Borghi, C. (2017). The management of hyperuricemia: back to the pathophysiology of uric acid. Current Medical Research and Opinion, 33(sup3), 1-4.
70. Mahmoud, H. H., Leverger, G., Patte, C., Harvey, E., & Lascombes, F. (1998). Advances in the management of malignancy-associated hyperuricaemia. British Journal of Cancer, 77(4), 18-20.
71. Emmerson, B. (1998). Hyperlipidaemia in hyperuricaemia and gout. Annals of the rheumatic diseases, 57(9), 509-510.
72. Bedir, A., Topbas, M., Tanyeri, F., Alvur, M., & Arik, N. (2003). Leptin might be a regulator of serum uric acid concentrations in humans. Japanese heart journal, 44(4), 527-536.
73. Dessein, P. H., Shipton, E. A., Stanwix, A. E., Joffe, B. I., & Ramokgadi, J. (2000). Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Annals of the rheumatic diseases, 59(7), 539-543.
74. Bobulescu, I. A., & Moe, O. W. (2012). Renal transport of uric acid: evolving concepts and uncertainties. Advances in chronic kidney disease, 19(6), 358-371.
75. Han, J., Liu, Y., Rao, F., Nievergelt, C. M., O’Connor, D. T., Wang, X., … & Wang, H. (2013). Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney international, 83(4), 733-740.
76. Cho, S. K., Kim, S., Chung, J. Y., & Jee, S. H. (2015). Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1. BMJ open, 5(11), e009360.
77. Tan, P. K., Ostertag, T. M., & Miner, J. N. (2016). Mechanism of high affinity inhibition of the human urate transporter URAT1. Scientific reports, 6(1), 1-13.
78. Phipps-Green, A. J., Merriman, M. E., Topless, R., Altaf, S., Montgomery, G. W., Franklin, C., … & Merriman, T. R. (2016). Twenty-eight loci that influence serum urate levels: analysis of association with gout. Annals of the rheumatic diseases, 75(1), 124-130.
79. Kolz, M., Johnson, T., Sanna, S., Teumer, A., Vitart, V., Perola, M., … & Gieger, C. (2009). Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS genetics, 5(6), e1000504.
80. Liu, R., O’Connell, M., Johnson, K., Pritzker, K., Mackman, N., & Terkeltaub, R. (2000). Extracellular signal–regulated kinase 1/extracellular signal–regulated kinase 2 mitogen‐activated protein kinase signaling and activation of activator protein 1 and nuclear factor κB transcription factors play central roles in interleukin‐8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 43(5), 1145-1155.
81. Cronstein, B. N., & Sunkureddi, P. (2013). Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases, 19(1), 19.
82. Busso, N., & Ea, H. K. (2011). The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). Reumatismo, 63(4), 230-237.
83. Ea, H. K. (2011). Mechanisms of gout inflammation. Presse Medicale (Paris, France: 1983), 40(9 Pt 1), 836-843.
84. Dalbeth, N., Lauterio, T. J., & Wolfe, H. R. (2014). Mechanism of action of colchicine in the treatment of gout. Clinical therapeutics, 36(10), 1465-1479.
85. Steiger, S., & Harper, J. L. (2014). Mechanisms of spontaneous resolution of acute gouty inflammation. Current rheumatology reports, 16(1), 1-7.
86. Doherty, M., Jansen, T. L., Nuki, G., Pascual, E., Perez-Ruiz, F., Punzi, L., … & Bardin, T. (2012). Gout: why is this curable disease so seldom cured?. Annals of the rheumatic diseases, 71(11), 1765-1770.
87. Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., … & Terkeltaub, R. (2012). 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care & research, 64(10), 1431-1446.
88. Khanna, D., Khanna, P. P., Fitzgerald, J. D., Singh, M. K., Bae, S., Neogi, T., … & Terkeltaub, R. (2012). 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis care & research, 64(10), 1447-1461.
89. Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., … & Bardin, T. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the rheumatic diseases, 76(1), 29-42.
90. De Vera, M. A., Marcotte, G., Rai, S., Galo, J. S., & Bhole, V. (2014). Medication adherence in gout: a systematic review. Arthritis care & research, 66(10), 1551-1559.
91. Zhu, Y., Zhang, Y., & Choi, H. K. (2010). The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology, 49(12), 2391-2399.
92. Beyl Jr, R. N., Hughes, L., & Morgan, S. (2016). Update on importance of diet in gout. The American journal of medicine, 129(11), 1153-1158.
93. Azadbakht, L., Mirmiran, P., Esmaillzadeh, A., Azizi, T., & Azizi, F. (2005). Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes care, 28(12), 2823-2831.
94. Kontogianni, M. D., Chrysohoou, C., Panagiotakos, D. B., Tsetsekou, E., Zeimbekis, A., Pitsavos, C., & Stefanadis, C. (2012). Adherence to the Mediterranean diet and serum uric acid: the ATTICA study. Scandinavian journal of rheumatology, 41(6), 442-449.
95. Kiltz, U., Smolen, J., Bardin, T., Solal, A. C., Dalbeth, N., Doherty, M., … & Braun, J. (2017). Treat-to-target (T2T) recommendations for gout. Annals of the rheumatic diseases, 76(4), 632-638.
96. Latourte, A., Bardin, T., & Richette, P. (2014). Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology, 53(11), 1920-1926.
97. Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013). Low-dose colchicine for secondary prevention of cardiovascular disease. Journal of the American College of Cardiology, 61(4), 404-410.
98. Richette, P., Perez-Ruiz, F., Doherty, M., Jansen, T. L., Nuki, G., Pascual, E., … & Bardin, T. (2014). Improving cardiovascular and renal outcomes in gout: what should we target?. Nature Reviews Rheumatology, 10(11), 654-661.
99. Richette, P., Brière, C., Hoenen-Clavert, V., Loeuille, D., & Bardin, T. (2007). Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. The Journal of rheumatology, 34(10), 2093-2098.
100. Sundy, J. S., Baraf, H. S., Yood, R. A., Edwards, N. L., Gutierrez-Urena, S. R., Treadwell, E. L., … & Becker, M. A. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Jama, 306(7), 711-720.
101. Vallon, V., & Thomson, S. C. (2017). Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia, 60(2), 215-225.
102. Ragab, G., Elshahaly, M., & Bardin, T. (2017). Gout: An old disease in new perspective–A review. Journal of advanced research, 8(5), 495-511.